Artificial intelligence is flooding cancer care with chatbots, virtual navigators, and digital companions. But before healthcare builds another platform, perhaps someone should ask whether patients actually trust any of this stuff.
Hollywood spent decades warning us that artificial intelligence would eventually kill everybody. From WarGames and The Terminator to 2001: A Space Odyssey and The Matrix, Gen X grew up expecting the machines to turn against humanity. Naturally, we responded by giving them our credit cards, genetic profiles, and medical histories.
Now Skynet has apparently opened a patient engagement division.
The oncology industry is experiencing an AI gold rush. Startups, technology companies, healthcare institutions, and investors are developing AI-powered patient navigators, virtual companions, symptom management tools, educational assistants, and personalized support platforms. Some offer genuinely promising ways to make cancer care more accessible and understandable. Others raise a question that healthcare has historically been remarkably good at avoiding: Does anybody actually want what we're building?
This isn't about artificial intelligence in drug discovery, molecular research, pathology, or clinical decision support. Those applications have enormous potential to improve cancer treatment. The concern here is patient-facing AI, particularly products promising to simplify the experience of living with cancer.
Patient Adoption Is Not Patient Trust
Research on public attitudes toward healthcare AI reveals an important distinction between using technology and trusting it. Patients may appreciate the convenience of asking an AI assistant to explain unfamiliar medical terminology, interpret information in a pathology report, or help prepare questions for an oncologist. That doesn't necessarily mean they trust the same technology to recommend treatment, protect sensitive information, or make consequential medical decisions.
For someone confronting a cancer diagnosis, the need for answers can be immediate and overwhelming. AI offers something traditional healthcare often cannot: information on demand, without appointment scheduling, telephone queues, or office hours.
But desperation can drive adoption without creating trust.
Healthcare organizations have spent decades measuring utilization, engagement, and satisfaction while frequently overlooking whether patients genuinely trust the institutions providing their care. Artificial intelligence risks accelerating that confusion. A platform may generate thousands of conversations and impressive engagement metrics without demonstrating that patients are better informed, more confident in their decisions, or experiencing fewer barriers to care.
The Oncology AI Branding Problem
As patient-facing AI products proliferate, differentiation becomes increasingly important. If multiple companies offer similar oncology assistants using comparable underlying technologies and promising nearly identical benefits, what makes a patient choose one over another?
The answer is unlikely to be another attractive interface or the words AI-powered in a marketing campaign.
Patients may place greater value on demonstrated accuracy, privacy protections, clinical credibility, recommendations from trusted healthcare professionals, and transparency about the organizations developing and funding these products. Independence may also matter, particularly when patients have reason to question whether an institution's commercial interests align with their own.
A chatbot developed by an insurance company, for example, doesn't automatically resolve a patient's distrust of that insurer's coverage decisions. A hospital's virtual assistant cannot compensate for confusing billing practices or inadequate access to care. Technology may improve communication, but it cannot manufacture institutional credibility.
As I put it in the accompanying essay, giving the bureaucracy a personality doesn't necessarily make it more trustworthy. Sometimes you've simply invented Clippy for medical bankruptcy.
Venture Capital, Patient Needs, and Competing Incentives
Investment is essential to developing reliable healthcare technology. But venture-backed companies are also expected to demonstrate growth, recurring revenue, scalability, and financial returns.
Cancer patients have a different set of priorities. They want accurate information, timely treatment, affordable care, meaningful support, and fewer administrative obstacles.
Those interests are not inherently incompatible. However, the industry's enthusiasm for user acquisition and engagement raises legitimate questions about how patient trust is measured, how product effectiveness is validated, and who remains accountable when something goes wrong.
The central challenge is not simply whether artificial intelligence can provide an answer. It's whether the answer is reliable, whether the patient understands its limitations, and whether the organization delivering it has earned the patient's confidence.
Building Technology Patients Have Reason to Trust
Patient-facing oncology AI could offer substantial benefits. Well-designed tools may help people understand treatment information, locate financial assistance, prepare for medical appointments, navigate insurance requirements, and identify questions that warrant professional attention.
But realizing that potential requires more than technological sophistication. It requires meaningful patient involvement in determining which problems deserve attention, independent evaluation of effectiveness, transparency about commercial relationships, and accountability for errors or misleading information.
After nearly 30 years working in cancer advocacy and healthcare, I've watched institutions repeatedly invite patients to participate in conversations about innovation while retaining control over the decisions that follow.
Artificial intelligence could become another chapter in that familiar story, or it could help change it.
Before building another oncology copilot, companion, navigator, or virtual assistant, the industry should be asking whether patients trust the organizations behind these products, whether the technology addresses problems patients consider important, and whether measurable improvements extend beyond engagement dashboards.
Because the last thing anyone with cancer needs is another technological marvel promising to transform their life while primarily enriching somebody else.
American healthcare already has an entire business model for that.
And unlike Skynet, it doesn't even need to become self-aware.
Matthew Zachary is the author of We the Patients: Understanding, Navigating, and Surviving America's Healthcare Nightmare (Wiley, 2026), and co-founder of We The Patients, an initiative focused on building independent civic power and political accountability for patients.
